Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study to Evaluate the Efficacy and Safety of ZL-3101 in Subjects With Subacute Eczema

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03134352
Recruitment Status : Completed
First Posted : April 28, 2017
Last Update Posted : January 24, 2019
Sponsor:
Information provided by (Responsible Party):
Zai Lab Pty. Ltd.

Brief Summary:
This is a double-blind, randomized, placebo-controlled multi-center phase IIA study to evaluate the clinical efficacy and safety of Fugan ointment versus placebo applied to involved skin of subjects with mild to moderate subacute eczema.

Condition or disease Intervention/treatment Phase
Eczema Drug: ZL-3101 Drug: Placebo Phase 2

Detailed Description:

In this study, patients will be recruited and randomized in a ratio of 2:2:1 into Fugan bid group (Fugan AM + Fugan PM), Fugan qd group (Fugan AM + Placebo PM), and placebo group (Placebo AM + Placebo PM). Randomization will be stratified by disease severity (mild IGA=2 vs. moderate IGA=3).

The patients will be given 3-week treatment and followed up for two weeks after the treatment.

Screening period is set as 1 week. Subjects will be given 3-week treatment and followed up for two weeks after the treatment.

Approximately 310 subjects will be randomized to achieve 250 evaluable subjects completing the study.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 290 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: A Multi-center, Randomized, Double-blind, Parallel, Placebo Controlled Phase II Study to Evaluate the Efficacy and Safety of Fugan Ointment (ZL-3101) in Subjects With Subacute Eczema
Actual Study Start Date : April 26, 2017
Actual Primary Completion Date : May 25, 2018
Actual Study Completion Date : September 10, 2018

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Eczema

Arm Intervention/treatment
Experimental: ZL-3101(Fugan) bid group
Fugan AM + Fugan PM
Drug: ZL-3101
A brown ointment, 10g/tube, 0.4g herb/g ointment, Topical
Other Name: Fugan ointment

Experimental: ZL-3101(Fugan) qd group
Fugan AM + Placebo PM
Drug: ZL-3101
A brown ointment, 10g/tube, 0.4g herb/g ointment, Topical
Other Name: Fugan ointment

Drug: Placebo
A brown ointment, 10g/tube, 0.02 g herb/g ointment (5% of Fugan active ointment), Topical

Placebo Comparator: placebo group
Placebo AM + Placebo PM
Drug: Placebo
A brown ointment, 10g/tube, 0.02 g herb/g ointment (5% of Fugan active ointment), Topical




Primary Outcome Measures :
  1. Eczema Area and Severity Index (EASI) score changes from baseline to day 21 [ Time Frame: 21 days ]
    To evaluate efficacy of Fugan ointment applied to involved skin of subjects with mild to moderate subacute eczema



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Male or female subjects between 18 and 65 years of age inclusive, at the time of signing the informed consent; from outpatient clinic;
  2. Subjects with a diagnosis of subacute eczema (Zhao 2001). Subacute eczema is often developed from improperly treated acute eczema or a few with presented subacute eczema from early on-set. Subacute eczema usually presents with papule, excoriations, crusting and pruritus. Occasionally patient will present with papulovesicle, blister and erosion. Patients also need to meet the requirement of:

    • Subjects must have body surface area (BSA) disease involvement between 3-10% (inclusive) as assessed by palm method;
    • IGA score of 2 or 3;
    • Skin lesions should be on the trunk or extremities, without palms/soles, face/scalp, and vulvar areas involved;
  3. Based on TCM theory (Zheng 2002), patients with TCM "damp - heat" symptoms to be included. It is subject to TCM investigator's assessment, and symptoms could be (but not limited to):

    • Main symptoms: erythema, pruritus, papule with less exudation;
    • Secondary symptoms: Mild infiltration, excoriations, crusting, papulovesicle, blister, irritability, thirst, yellowish urine and dry stool;
    • Tongue and pulse analysis: red tongue with yellow or yellowish coating, slippery pulse model;
  4. Subjects are general in good health; except for eczema, there are no other health conditions that possibly interfere with the study results;
  5. A signed and dated written informed consent is obtained from the subject.

Exclusion Criteria:

  1. The subject presents with or has the history of any systemic disorders or active skin diseases (e.g. psoriasis) that would in any way confound interpretation of the study results;
  2. The subject has a current complication of overt bacterial, fungal or viral infection for which treatment with anti-infective are indicated;
  3. Have the history of hepatic and kidney function insufficiency, hepatic dysfunction ALT or AST>1.5 ULN, kidney function BUN, Cr>1.5 ULN;
  4. QT interval corrected according to Bazett's formula or QT interval corrected according to Fridericia's formula ≥450 msec; or QTc ≥480 msec in subjects with bundle branch block;
  5. Have the history or examination verified by physical and screening of clinically significant cardiovascular, pulmonary, gastrointestinal, liver, renal, hematological, neurological, abnormalities and psychology disorders which will interfere with the efficacy and/or safety of the individual subject;
  6. History of allergy to any component of test medications to be used in the study;
  7. The subject has been exposed to below therapy within the set timeframe:

    • Systemic administration of anti-histamine agents 1 week
    • Systemic administration of corticosteroid 4 weeks;
    • Topical corticosteroid agents administered in the diseased skin 1 week;
    • Systemic administration of immunosuppressive drugs 4 weeks;
    • Topical immunosuppressive drugs administered in the diseased skin 1 week;
    • Systemic administration of any TCM drugs 2 weeks;
    • Topical administration of any TCM drugs 1 week;
    • UV therapy 4 weeks

    The use of inhaled/intranasal steroids is permitted prior to and during the conduct of the study if already being used by the subject.

  8. The subject has a past history of alcohol or drug abuse;
  9. Pregnant women (as confirmed by a positive urine human chorionic gonadotrophin (HCG) test), women who are breast feeding, or sexually active women of child bearing potential who are not practicing an acceptable method of birth control (birth control pill, patch, implant, barrier with spermicidal jelly, IUD, etc.), as determined by the investigator. An acceptable method of birth control must be used during the entire study in sexually active women of childbearing potential. A woman of childbearing potential is defined as one who is biologically capable of becoming pregnant. Abstinence is considered as a medically acceptable form of contraception;
  10. The subject has received an investigational drug or participated in any other research trial within 30 days;
  11. Other subjects that investigator deemed as unsuitable for the trial;
  12. Subject's EASI score reaches 2 and above for lichenification and/or edema.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03134352


Locations
Layout table for location information
China
Beijing Hospital of Traditional Chinese Medicine
Beijing, China
Dongzhimen Hospital, Beijing University of Chinese Medicine
Beijing, China
Guang'anmen Hospital, China Academy of Chinese Medical Sciences
Beijing, China
Jiangsu Province Hospital of Traditional Chinese Medicine
Nanjing, China
Shanghai Dermatology Hospital
Shanghai, China
Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of TCM
Shanghai, China
Sponsors and Collaborators
Zai Lab Pty. Ltd.
Investigators
Layout table for investigator information
Principal Investigator: Bin Li Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of TCM

Layout table for additonal information
Responsible Party: Zai Lab Pty. Ltd.
ClinicalTrials.gov Identifier: NCT03134352     History of Changes
Other Study ID Numbers: ZL-3101-001
First Posted: April 28, 2017    Key Record Dates
Last Update Posted: January 24, 2019
Last Verified: January 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Zai Lab Pty. Ltd.:
subacute

Additional relevant MeSH terms:
Layout table for MeSH terms
Eczema
Dermatitis
Skin Diseases
Skin Diseases, Eczematous